Minister of Industry Work Visit to PT Kalbio Global Medika
Minister of Industry, Agus Gumiwang Kartasasmita, (right) accompanied by the Director General of the Pharmaceutical Chemical and Textile Industry, Muhammad Khayam, (left) chatted with the President Director of PT Kalbe Farma Tbk, Vidjongtius, (middle) during a working visit at PT Kalbio Global Medika in Cikarang, March 11, 2020. The government, according to the Minister of Industry, has launched a program to accelerate the development of the strategic sector through the issuance of the Economic Policy Package XI, as outlined in Presidential Instruction (Inpres) Number 6 of 2016 concerning the Acceleration of Development of the Pharmaceutical and Medical Devices Industry (Alkes).
Minister of Industry, Agus Gumiwang Kartasasmita, and the President Commissioner of PT Kalbe Farma Tbk, Irawati Setiady, inspect the laboratory of PT Kalbio Global Medika during a working visit to PT Kalbio Global Medika in Cikarang on March 11, 2020. PT Kalbio Global Medika is a subsidiary of PT Kalbe Farma Tbk that specializes in the manufacture of biological products, from medicinal raw materials to finished products.
Minister of Industry, Agus Gumiwang Kartasasmita (second left), accompanied by the Director General of Pharmaceutical Chemical and Textile Industry, Muhammad Khayam (right), chatted with the Founder of Kalbe Group, Dr. Boenjamin Setiawan (left), and the President Director of PT Kalbe Farma Tbk, Vidjongtius (second right), during a working visit to PT Kalbio Global Medika in Cikarang on March 11, 2020.
KGM at a Glance
Kalbio Global Medika (KGM) is one of the first and the pioneer of biopharmaceuticals in Indonesia, established in 2014 and inaugurated officially in 2018 by the President of the Republic of Indonesia, Ir. Joko Widodo. KGM is part of the Kalbe Group, a subsidiary of PT Kalbe Genexine Biologics (KGbio), which is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside US/Canada, Western Europe, and China. KGM is an Innovative CDMO, equipped with CMC and scale-up capabilities plugged into Boston biotech ecosystem and state-of-the-art facility to enhance efficiency and productivity. With API manufacturing, formulation, fill and finish capabilities of biosimilar and novel biologics, averaging 10 million units of syringes, cartridges, and vials, KGM supplies local and international markets.
Kalbe at a Glance
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division.
Kalbe has also developed a B2B-based digital services ecosystem for the society: EMOS and KlikDokter, a B2C service. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. KlikDokter is a digital platform for healthcare services focusing on telemedicine, which provides health consultation and products that are needed by the society.
Kalbe now has more than 40 subsidiaries and 15 international-standard production facilities, supported by around 16,000 employees in 76 branches throughout Indonesia. Kalbe’s shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991.
Reference:
Kunjungan Kerja Menteri Perindustrian di PT Kalbio Global Medika